

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 August 2025 (14.08.2025)



(10) International Publication Number
WO 2025/169133 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/IB2025/051304

(22) International Filing Date:
07 February 2025 (07.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24156795.7 09 February 2024 (09.02.2024) EP

(71) Applicants: **ASTRAZENECA AB** [SE/SE]; SE-151-85 Södertälje (SE). **SILENCE THERAPEUTICS GMBH** [DE/DE]; Robert-Rössle-Strasse 10, 13125 Berlin (DE).

(72) Inventors: **FOINQUINOS, Ariana**; c/o AstraZeneca AB, SE-151 85 Södertälje (SE). **HURT-CAMEJO, Eva**; c/o AstraZeneca AB, SE-151 85 Södertälje (SE). **PENG, Xiao-Rong**; c/o AstraZeneca AB, SE-151 85 Södertälje (SE). **MORRISON, Eliot**; c/o Silence Therapeutics GmbH, Robert-Rössle-Strasse 10, 13125 Berlin (DE). **GIANNAKOPOULOS, Stavros**; c/o Silence Therapeutics GmbH, Robert-Rössle-Strasse 10, 13125 Berlin (DE). **DAMES, Sibylle**; c/o Silence Therapeutics GmbH, Robert-Rössle-Strasse 10, 13125 Berlin (DE). **JOHANNSEN, Timo**; c/o Silence Therapeutics GmbH, Robert-Rössle-Strasse 10, 13125 Berlin (DE). **BETHGE, Lucas**; c/o Silence Therapeutics GmbH, Robert-Rössle-Strasse 10, 13125 Berlin (DE). **SCHUBERT, Steffen**; c/o Silence Therapeutics GmbH, Robert-Rössle-Strasse 10, 13125 Berlin (DE). **WIKSTRÖM LINDHOLM, Marie**; c/o Silence Therapeutics GmbH, Robert-Rössle-Strasse 10, 13125 Berlin (DE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Eastbrook House, Shaftesbury Road, Cambridge, Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: DOUBLE-STRANDED RNAI AGENTS AND COMPOSITIONS FOR REDUCING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND METHODS OF USE THEREOF

(57) Abstract: There are disclosed certain double-stranded RNA (dsRNA) or siRNA agents for inhibition of angiotensin-like 3 gene expression, compositions that include angiotensin-like 3 agents and methods of use thereof. The double-stranded RNA (dsRNA) or siRNA agents are particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions as well as in the treatment of heart failure and chronic kidney disease.

WO 2025/169133 A1